



Tumor Vaccine Development, Immune-Based Therapies and Immune Markers

Guest Editors:

Dr. Marco Carlo Merlano

Scientific Direction, Candiolo
Cancer Institute (FPO-IRCCS),
Candiolo, Italy

Dr. Ornella Garrone

Medical Oncology, Fondazione
IRCCS Ca' Granda Ospedale
Maggiore Policlinico, Milano, Italy

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editors

The significance of immunotherapy in this field is increasing, and the importance of understanding the interaction between tumor cells and the immune system is dramatically growing. A deeper understanding of the multiple immunosuppressive mechanisms leading to tumor escape is paving the way for the development of an incredible number of new immunotherapies.

Similarly, the enormous ongoing effort to identify reliable markers of response will enable personalized therapies. Finally, after many disappointing experiences in the past, greater knowledge of the tumor microenvironment and of the immune response mechanisms have improved the expectations which can be placed on anti-tumor vaccines.

In combination with the other strategies, including chemotherapy, monoclonal antibodies, radiation therapy, and different immunotherapeutic approaches involving immune checkpoint inhibitor therapy, cancer vaccines will become soon an important new tool in fighting cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com